Andrew Oxtoby - Feb 28, 2023 Form 4 Insider Report for CHINOOK THERAPEUTICS, INC. (KDNY)

Role
Chief Commercial Officer
Signature
/s/ Kirk Schumacher, Attorney-in-Fact
Stock symbol
KDNY
Transactions as of
Feb 28, 2023
Transactions value $
$0
Form type
4
Date filed
3/2/2023, 04:00 PM
Previous filing
Feb 16, 2023
Next filing
Aug 11, 2023

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction KDNY Stock Option (right to buy) Award $0 +160K $0.00 160K Feb 28, 2023 Common Stock 160K $21.82 Direct F1
transaction KDNY Restricted Stock (RSU)(Common Stock) Award $0 +40K $0.00 40K Feb 28, 2023 Common Stock 40K Direct F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The stock option vests as to 25% of the total shares on February 28, 2024, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
F2 Each RSU represents a contingent right to receive one (1) share of the Issuer's Common Stock upon settlement.
F3 The RSUs vests as to one-third (1/3) of the total restricted stock units in equal annual installments beginning on February 28, 2024, until fully vested subject to the Reporting Person's provision of service to the Issuer on each vesting date.